Bruton’s tyrosine kinase inhibition for the treatment of rheumatoid arthritis

Laura C. Arneson, Kristen J. Carroll, Eric M. Ruderman*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Bruton’s tyrosine kinase (BTK) inhibitors are an emerging class of drugs that inhibit B cell receptor activation, FC-γ receptor signaling, and osteoclast proliferation. Following on approval for treatment of hematologic malignancies, BTK inhibitors are now under investigation to treat a number of different autoimmune diseases, including rheumatoid arthritis (RA). While the results of BTK inhibitors in RA animal models have been promising, the ensuing human clinical trial outcomes have been rather equivocal. This review will outline the mechanisms of BTK inhibition and its potential impact on immune mediated disease, the types of BTK inhibitors being studied for RA, the findings from both preclinical and clinical trials of BTK inhibitors in RA, and directions for future research.

Original languageEnglish (US)
Pages (from-to)333-342
Number of pages10
JournalImmunoTargets and Therapy
StatePublished - 2021


  • Acalabrutinib
  • Bruton’s tyrosine kinase
  • Evobrutinib
  • Fenebrutinib
  • Rheumatoid arthritis
  • Spebrutinib

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Bruton’s tyrosine kinase inhibition for the treatment of rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this